Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,856.80
(
-0.06%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.39
(
5.19%
)
Bitcoin
75,685.11
(
-0.27%
)
News Focus
News Focus
Post# of 822279
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

barnstormer

Send PM Follow Ignore
Followers 21
Posts 1010
Boards Moderated 0
Alias Born 09/20/2005

barnstormer

Member Level

Re: seekinganswers post# 787342

Tuesday, 09/09/2025 3:23:41 PM

Tuesday, September 09, 2025 3:23:41 PM

Post# of 822279
All the same old argument. PFS is the gold standard. If the trial doesn't meet that standard, it fails. No exceptions. OS results don't matter, regardless of the results. Also did a little research on the authors/contributors and found some receive compensation or honorarium from some of the big pharma's that would benefit from DCx-L's failure.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News